Ideaya Biosciences' Darovasertib Combination Data Profile is 'Highly Compelling,' Wedbush Says

MT Newswires Live05-06

Ideaya Biosciences' (IDYA) darovasertib plus crizotinib combination's overall data profile is "highly compelling" and data-to-date supports accelerated approval, Wedbush said in a Tuesday note.

The company plans to submit its new drug application for darovasertib in H2 and has announced alignment with the US Food and Drug Administration to review the NDA under the real-time oncology review program, Wedbush noted.

Outside of darovasertib, Wedbush said it is looking forward to a clinical update from ongoing Chinese studies investigating IDE849 by partner Jiangsu Hengrui at a medical conference in H2, as well as registrational trial initiations in 2027.

"We remain excited for the extensive clinical development across pipeline assets, as well as a nearing potential approval for darovasertib," Wedbush analysts said.

The brokerage maintained the company's outperform rating with a $58 price target.

Price: 28.01, Change: -0.89, Percent Change: -3.08

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633940330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633940330","market":"fut","top_or_hot":-1,"title":"Ideaya Biosciences' Darovasertib Combination Data Profile is 'Highly Compelling,' Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Ideaya Biosciences' (IDYA) darovasertib plus crizotinib combination's overall data profile is \"highly compelling\" and data-to-date supports accelerated approval, Wedbush said in a Tuesday note.</p><p>The company plans to submit its new drug application for darovasertib in H2 and has announced alignment with the US Food and Drug Administration to review the NDA under the real-time oncology review program, Wedbush noted.</p><p>Outside of darovasertib, Wedbush said it is looking forward to a clinical update from ongoing Chinese studies investigating IDE849 by partner <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> at a medical conference in H2, as well as registrational trial initiations in 2027.</p><p>\"We remain excited for the extensive clinical development across pipeline assets, as well as a nearing potential approval for darovasertib,\" Wedbush analysts said.</p><p>The brokerage maintained the company's outperform rating with a $58 price target.</p><p>Price: 28.01, Change: -0.89, Percent Change: -3.08</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ideaya Biosciences' Darovasertib Combination Data Profile is 'Highly Compelling,' Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIdeaya Biosciences' Darovasertib Combination Data Profile is 'Highly Compelling,' Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-06 01:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ideaya Biosciences' (IDYA) darovasertib plus crizotinib combination's overall data profile is \"highly compelling\" and data-to-date supports accelerated approval, Wedbush said in a Tuesday note.</p><p>The company plans to submit its new drug application for darovasertib in H2 and has announced alignment with the US Food and Drug Administration to review the NDA under the real-time oncology review program, Wedbush noted.</p><p>Outside of darovasertib, Wedbush said it is looking forward to a clinical update from ongoing Chinese studies investigating IDE849 by partner <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> at a medical conference in H2, as well as registrational trial initiations in 2027.</p><p>\"We remain excited for the extensive clinical development across pipeline assets, as well as a nearing potential approval for darovasertib,\" Wedbush analysts said.</p><p>The brokerage maintained the company's outperform rating with a $58 price target.</p><p>Price: 28.01, Change: -0.89, Percent Change: -3.08</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2633940330","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633940330","pubTimestamp":1778002449,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ideaya Biosciences'  darovasertib plus crizotinib combination's overall data profile is \"highly compelling\" and data-to-date supports accelerated approval, Wedbush said in a Tuesday note.The company plans to submit its new drug application for darovasertib in H2 and has announced alignment with the US Food and Drug Administration to review the NDA under the real-time oncology review program, Wedbush noted.Outside of darovasertib, Wedbush said it is looking forward to a clinical update from ongoing Chinese studies investigating IDE849 by partner Jiangsu Hengrui at a medical conference in H2, as well as registrational trial initiations in 2027.\"We remain excited for the extensive clinical development across pipeline assets, as well as a nearing potential approval for darovasertib,\" Wedbush analysts said.The brokerage maintained the company's outperform rating with a $58 price target.Price: 28.01, Change: -0.89, Percent Change: -3.08","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"Wedbush表示，Ideaya Biosciences的Darovasertib组合数据“非常引人注目”","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1},"content_text":"Ideaya Biosciences' (IDYA) darovasertib plus crizotinib combination's overall data profile is \"highly compelling\" and data-to-date supports accelerated approval, Wedbush said in a Tuesday note.The company plans to submit its new drug application for darovasertib in H2 and has announced alignment with the US Food and Drug Administration to review the NDA under the real-time oncology review program, Wedbush noted.Outside of darovasertib, Wedbush said it is looking forward to a clinical update from ongoing Chinese studies investigating IDE849 by partner Jiangsu Hengrui at a medical conference in H2, as well as registrational trial initiations in 2027.\"We remain excited for the extensive clinical development across pipeline assets, as well as a nearing potential approval for darovasertib,\" Wedbush analysts said.The brokerage maintained the company's outperform rating with a $58 price target.Price: 28.01, Change: -0.89, Percent Change: -3.08","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633940330","isCrawlerRequest":true}